These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 2552378

  • 1. [Bactericidal effect of daptomycin (LY 146032) compared with vancomycine and teicoplanin against gram-positive bacteria].
    Caillon J, Juvin ME, Pirault JL, Drugeon HB.
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):540-8. PubMed ID: 2552378
    [Abstract] [Full Text] [Related]

  • 2. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F, Aguilar L, González N, Giménez MJ, Torrico M, Alou L, Sevillano D, Vallejo P, Prieto J.
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT, Liao CH, Teng LJ, Hsueh PR.
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
    Brauers J, Kresken M, Menke A, Orland A, Weiher H, Morrissey I.
    Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Everninomicin, a new oligosaccharide antibiotic: its antimicrobial activity, post-antibiotic effect and synergistic bactericidal activity.
    Nakashio S, Iwasawa H, Dun FY, Kanemitsu K, Shimada J.
    Drugs Exp Clin Res; 1995 Mar; 21(1):7-16. PubMed ID: 7796712
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
    Leuthner KD, Cheung CM, Rybak MJ.
    J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
    Hodinka RL, Jack-Wait K, Wannamaker N, Walden TP, Gilligan PH.
    Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
    [Abstract] [Full Text] [Related]

  • 12. [Bactericidal activity of daptomycin and vancomycin alone or in combination with tobramycin, netilmicin or ampicillin against enterococcus].
    Duez JM, Péchinot A, Siébor E, Cordin X, Kazmierczak A.
    Pathol Biol (Paris); 1989 Apr; 37(4):263-8. PubMed ID: 2543946
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of in vitro activity of teicoplanin against recent clinical isolates.
    Nani E, Amato G, Anzivino D, Covelli B, Lembo M.
    Chemioterapia; 1988 Feb; 7(1):20-3. PubMed ID: 2967737
    [Abstract] [Full Text] [Related]

  • 14. [The invitro activity of teicoplanin and vancomycin against gram positive microorganisms (corrected)].
    Kayaokay Y, Hasçelik G, Gür D, Akalin E.
    Mikrobiyol Bul; 1991 Oct; 25(4):321-5. PubMed ID: 1839050
    [Abstract] [Full Text] [Related]

  • 15. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
    Bartoloni A, Colao MG, Orsi A, Dei R, Giganti E, Parenti F.
    J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci.
    Vouillamoz J, Moreillon P, Giddey M, Entenza JM.
    J Antimicrob Chemother; 2006 Dec; 58(6):1208-14. PubMed ID: 17030515
    [Abstract] [Full Text] [Related]

  • 17. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
    Pohlod DJ, Saravolatz LD, Somerville MM.
    J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
    [Abstract] [Full Text] [Related]

  • 18. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.
    Tyrrell KL, Citron DM, Warren YA, Fernandez HT, Merriam CV, Goldstein EJ.
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2728-31. PubMed ID: 16870765
    [Abstract] [Full Text] [Related]

  • 19. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
    Machka K, Braveny I.
    Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
    [Abstract] [Full Text] [Related]

  • 20. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK.
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.